217 related articles for article (PubMed ID: 33727604)
21. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
22. No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors.
Martinez-Becerra P; Vaquero J; Romero MR; Lozano E; Anadon C; Macias RI; Serrano MA; Grañé-Boladeras N; Muñoz-Bellvis L; Alvarez L; Sangro B; Pastor-Anglada M; Marin JJ
Mol Pharm; 2012 Jun; 9(6):1693-704. PubMed ID: 22524153
[TBL] [Abstract][Full Text] [Related]
23. PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cells.
Stafman LL; Williams AP; Marayati R; Aye JM; Stewart JE; Mroczek-Musulman E; Beierle EA
PLoS One; 2019; 14(4):e0214469. PubMed ID: 30969990
[TBL] [Abstract][Full Text] [Related]
24. 2-Thioxothiazolidin-4-one Analogs as Pan-PIM Kinase Inhibitors.
Yun Y; Hong VS; Jeong S; Choo H; Kim S; Lee J
Chem Pharm Bull (Tokyo); 2021; 69(9):854-861. PubMed ID: 34470949
[TBL] [Abstract][Full Text] [Related]
25. Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells.
Lee M; Lee KH; Min A; Kim J; Kim S; Jang H; Lim JM; Kim SH; Ha DH; Jeong WJ; Suh KJ; Yang YW; Kim TY; Oh DY; Bang YJ; Im SA
Cancer Res Treat; 2019 Apr; 51(2):451-463. PubMed ID: 29879757
[TBL] [Abstract][Full Text] [Related]
26. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.
Keeton EK; McEachern K; Dillman KS; Palakurthi S; Cao Y; Grondine MR; Kaur S; Wang S; Chen Y; Wu A; Shen M; Gibbons FD; Lamb ML; Zheng X; Stone RM; Deangelo DJ; Platanias LC; Dakin LA; Chen H; Lyne PD; Huszar D
Blood; 2014 Feb; 123(6):905-13. PubMed ID: 24363397
[TBL] [Abstract][Full Text] [Related]
27. PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.
Warfel NA; Sainz AG; Song JH; Kraft AS
Mol Cancer Ther; 2016 Jul; 15(7):1637-47. PubMed ID: 27196781
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of PIM1 blocks the autophagic flux to sensitize glioblastoma cells to ABT-737-induced apoptosis.
Remy J; Linder B; Weirauch U; Konovalova J; Marschalek R; Aigner A; Kögel D
Biochim Biophys Acta Mol Cell Res; 2019 Feb; 1866(2):175-189. PubMed ID: 30389373
[TBL] [Abstract][Full Text] [Related]
29. PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma.
Brunen D; de Vries RC; Lieftink C; Beijersbergen RL; Bernards R
Mol Cancer Ther; 2018 Apr; 17(4):849-857. PubMed ID: 29440296
[TBL] [Abstract][Full Text] [Related]
30. Hepatocyte growth factor protects hepatoblastoma cells from chemotherapy-induced apoptosis by AKT activation.
Grotegut S; Kappler R; Tarimoradi S; Lehembre F; Christofori G; Von Schweinitz D
Int J Oncol; 2010 May; 36(5):1261-7. PubMed ID: 20372801
[TBL] [Abstract][Full Text] [Related]
31. AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK.
Yadav AK; Kumar V; Bailey DB; Jang BC
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30654529
[TBL] [Abstract][Full Text] [Related]
32. Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition.
Iqbal A; Eckerdt F; Bell J; Nakano I; Giles FJ; Cheng SY; Lulla RR; Goldman S; Platanias LC
Oncotarget; 2016 May; 7(22):33192-201. PubMed ID: 27120806
[TBL] [Abstract][Full Text] [Related]
33. Development of a drug resistance model for hepatoblastoma.
Eicher C; Dewerth A; Kirchner B; Warmann SW; Fuchs J; Armeanu-Ebinger S
Int J Oncol; 2011 Feb; 38(2):447-54. PubMed ID: 21132272
[TBL] [Abstract][Full Text] [Related]
34. Comparative activity of cisplatin, ifosfamide, doxorubicin, carboplatin, and etoposide in heterotransplanted hepatoblastoma.
Fuchs J; Wenderoth M; von Schweinitz D; Haindl J; Leuschner I
Cancer; 1998 Dec; 83(11):2400-7. PubMed ID: 9840541
[TBL] [Abstract][Full Text] [Related]
35. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
Kreuz S; Holmes KB; Tooze RM; Lefevre PF
Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
[TBL] [Abstract][Full Text] [Related]
36. Pim-1 plays a pivotal role in hypoxia-induced chemoresistance.
Chen J; Kobayashi M; Darmanin S; Qiao Y; Gully C; Zhao R; Yeung SC; Lee MH
Oncogene; 2009 Jul; 28(28):2581-92. PubMed ID: 19483729
[TBL] [Abstract][Full Text] [Related]
37. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
[TBL] [Abstract][Full Text] [Related]
38. PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases.
Martín-Sánchez E; Odqvist L; Rodríguez-Pinilla SM; Sánchez-Beato M; Roncador G; Domínguez-González B; Blanco-Aparicio C; García Collazo AM; Cantalapiedra EG; Fernández JP; Curiel del Olmo S; Pisonero H; Madureira R; Almaraz C; Mollejo M; Alves FJ; Menárguez J; González-Palacios F; Rodríguez-Peralto JL; Ortiz-Romero PL; Real FX; García JF; Bischoff JR; Piris MA
PLoS One; 2014; 9(11):e112148. PubMed ID: 25386922
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological inhibition of beta-catenin in hepatoblastoma cells.
Ellerkamp V; Lieber J; Nagel C; Wenz J; Warmann SW; Fuchs J; Armeanu-Ebinger S
Pediatr Surg Int; 2013 Feb; 29(2):141-9. PubMed ID: 23266718
[TBL] [Abstract][Full Text] [Related]
40. Altered expression of resistance associated genes in hepatoblastoma xenografts incorporated into mice following treatment with adriamycin or cisplatin.
Bader P; Fuchs J; Wenderoth M; von Schweinitz D; Niethammer D; Beck JF
Anticancer Res; 1998; 18(4C):3127-32. PubMed ID: 9713521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]